GGrantIndex
← Search

Molecular Pharmacology Shared Resource

$1P30FY2023CANIH

University Of California At Davis, Davis CA

Investigators

Linked publications, trials & patents

Paper 39725713Paper 39620216Paper 39616300Paper 39488208Paper 39453739Paper 39440945Paper 39384967Paper 39383000Paper 39350111Paper 39345479Paper 39345391Paper 39257973Paper 39252929Paper 39217266Paper 39177582Paper 39168154Paper 39108503Paper 39103353Paper 39056190Paper 39046599Paper 39012466Paper 38990223Paper 38979288Paper 38969563Paper 38947002Paper 38885336Paper 38877132Paper 38865710Paper 38843382Paper 38826195Paper 38803393Paper 38798575Paper 38780011Trial NCT07304011Trial NCT07258446Trial NCT07209215Trial NCT07189195Trial NCT07145112Trial NCT06905509Trial NCT06854159Trial NCT06211335Trial NCT06178354Trial NCT06173362Trial NCT06173349Trial NCT06103682Trial NCT06103669Trial NCT06067776Trial NCT05967533Trial NCT05843448Trial NCT05600686Trial NCT05479578Trial NCT05110781Trial NCT05101356Trial NCT05052528Trial NCT04964505Trial NCT04905810Trial NCT04856189Trial NCT04716699Trial NCT04587687Trial NCT04578600Trial NCT04552704Trial NCT04450173Trial NCT04410302Trial NCT04186988Trial NCT04050085Trial NCT04030559Trial NCT03695250Trial NCT03359460Trial NCT03299088Trial NCT03164486Trial NCT03123978Trial NCT02997761Trial NCT02935205Trial NCT02823990Trial NCT02807805Trial NCT02569723Trial NCT02400814Trial NCT02364609Trial NCT02348255Trial NCT02339168Trial NCT02178241Trial NCT02077998Trial NCT01924260Trial NCT01923337Trial NCT01911507Trial NCT01008566Trial NCT00918645Trial NCT00810719Trial NCT00804310Trial NCT00795665Trial NCT00628654Trial NCT00467077Trial NCT00408499Trial NCT00390429Trial NCT00389922Trial NCT00388115Trial NCT00388089Trial NCT00387660Trial NCT00387322Trial NCT00376727

Abstract

MOLECULAR PHARMACOLOGY SHARED RESOURCE (MPSR) PROJECT SUMMARY/ABSTRACT The Molecular Pharmacology Shared Resource (MPSR) at the UC Davis Comprehensive Cancer Center (UCDCCC) has centralized services to conduct clinical pharmacokinetic (PK)/pharmacodynamic (PD) studies and preclinical modeling of new therapeutics. Understanding PK/PD properties of individual drugs is essential for preclinical and clinical drug development, as well as clinical practice of precision medicine in cancer. Many clinical studies conducted at the UCDCCC, including investigator-initiated clinical trials (IIT) or National Cancer Institute (NCI)-funded Experimental Therapeutics Clinical Trials Network (ETCTN) trails, and the National Clinical Trials Network (NCTN) trials for which UCDCCC is a Lead Academic Participating Site, involve the assessment of PK/PD properties and on-target pharmacological actions. Meanwhile, defining drug metabolism (DM) and PK/PD characteristics in appropriate preclinical models is vital before translating new therapeutic drugs into clinical investigations. The MPSR provides comprehensive services for high-quality collection, processing and analysis of clinical specimens from trial patients to assess clinical PK/PD, and preclinical assessment of novel therapeutics and regimens, including DM/PK/PD, on-target mechanisms, biomarkers, drug-drug interactions (DDI) and combination effects. In addition, the MPSR provides support for IITs by helping with protocol and assay development. Very recent acquisition of a state-of-the-art, live-cell metabolic assay platform, the Seahorse XFe Analyzer, will further strengthen basic and translational research in the areas of cancer metabolism at UCDCCC. Oversight and management of the MPSR is provided by the Director, Aiming Yu, PhD, a world leader in the fields of DM/PK, studying molecular mechanisms of DM/PK/PD and anticancer pharmacology, and the Technical Manager, Anthony Martinez, BS, the Assistant Director of the Office of Clinical Research (OCR), with over 7 years' experience in clinical trials and 20 years' in cancer research. The Specific Aims for the MPSR are: 1) Clinical Trial Specimen Management, in which the MPSR oversees biospecimens collection, processing and storage for patients enrolled on clinical trials conducted at UCDCCC; 2) Protocol Development and Clinical PK/PD studies, in which the MPSR supports study design, and protocol development, develops new in-house assays and conducts targeted analyses of drugs, metabolites and biomarkers, performs PK/PD data analysis and interpretation; and 3) Preclinical Modeling in which the MPSR evaluates new agents and treatments for precision medicine that are translatable to the clinic.

View original record on NIH RePORTER →